BIOREVERT INC. IS FEATURED AT STARTUP SPOTLIGHT OF ASIA BIO 2024
https://informaconnect.com/asia-bio-partnering-forum/startup-spotlight/
Singapore / Apr. 24th, 2024 – Biorevert Inc. (“biorevert”) is featured as a semi-finalist at Startup Spotlight Competition of the Asia Bio Partnering Forum. The Co-founder and Chief Global Strategist of biorevert, Sea Choi, Ph.D., will be presenting at the Asia Bio Partnering Forum in Singapore on April 25th, 2024.
Asia Bio Partnering Forum, organized by EBD Group, is a partnering event to build strong start and gateway to Asia’s emerging innovation for biotech and pharma leaders around the world. The Asia Bio Partnering Forum is focused on driving advances in innovative therapies by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference will take place in Singapore this year from April 24th to 25th.
“The Asia Bio Partnering Forum program is developed to highlight the powerful rise of innovation in the Asia life science market,” said Anna Chrisman, President of Life Sciences of EBD group. “The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies in Asia. We are very excited to feature biorevert as one of semi-final startups for pitching in front of the Asia Bio Partnering Forum Audience during the upcoming Startup Spotlight competition in Singapore.”
The details of the biorevert presentation at the Asia Bio Partnering Forum are as follows:
Date: Thursday, April 25th, 2024
Time: 9:00 AM
Location: Marina Bay Sands Convention Center (Room 3103/3104)
ABOUT biorevert.
Biorevert is a faculty start-up biotech company with their novel first-in-class targets in colon, lung, and liver cancers identified by their AI- and systems biology-based platform called MObyDiCK platform.
MObyDiCK, Mechanistic target Optimization by Discovering and Controlling Network, is biorevert’s innovative proprietary platform for first-in-class target identification and its mechanism of actions (MOA). Once it’s optimized, biorevert plans to further validate their platform by enhancing its built-in drug discovery algorithms for a potential public release as a service in mid 2025.
Biorevert currently has seven pipelines under development both autonomously and collaboratively with leading biotech companies in south Korea. Four of their pipelines in the process of hit-finding, and other three pipelines are in the hit-to-lead process. They are also autonomously developing one of their pipelines as a small molecule and a gene therapy using adeno-associated virus, which is currently in in vivo Proof of Concept process.
For further information, please visit www.biorevert.com.
Contacts
Biorevert
Sea Choi
Co-founder and Chief Global Strategist
T +82 70-8787-8252
Email: cgs@biorevert.com
BIOREVERT INC. IS FEATURED AT STARTUP SPOTLIGHT OF ASIA BIO 2024
https://informaconnect.com/asia-bio-partnering-forum/startup-spotlight/
Singapore / Apr. 24th, 2024 – Biorevert Inc. (“biorevert”) is featured as a semi-finalist at Startup Spotlight Competition of the Asia Bio Partnering Forum. The Co-founder and Chief Global Strategist of biorevert, Sea Choi, Ph.D., will be presenting at the Asia Bio Partnering Forum in Singapore on April 25th, 2024.
Asia Bio Partnering Forum, organized by EBD Group, is a partnering event to build strong start and gateway to Asia’s emerging innovation for biotech and pharma leaders around the world. The Asia Bio Partnering Forum is focused on driving advances in innovative therapies by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference will take place in Singapore this year from April 24th to 25th.
“The Asia Bio Partnering Forum program is developed to highlight the powerful rise of innovation in the Asia life science market,” said Anna Chrisman, President of Life Sciences of EBD group. “The Startup Spotlight is a pitch competition featuring the most innovative startup biotech companies in Asia. We are very excited to feature biorevert as one of semi-final startups for pitching in front of the Asia Bio Partnering Forum Audience during the upcoming Startup Spotlight competition in Singapore.”
The details of the biorevert presentation at the Asia Bio Partnering Forum are as follows:
Date: Thursday, April 25th, 2024
Time: 9:00 AM
Location: Marina Bay Sands Convention Center (Room 3103/3104)
ABOUT biorevert.
Biorevert is a faculty start-up biotech company with their novel first-in-class targets in colon, lung, and liver cancers identified by their AI- and systems biology-based platform called MObyDiCK platform.
MObyDiCK, Mechanistic target Optimization by Discovering and Controlling Network, is biorevert’s innovative proprietary platform for first-in-class target identification and its mechanism of actions (MOA). Once it’s optimized, biorevert plans to further validate their platform by enhancing its built-in drug discovery algorithms for a potential public release as a service in mid 2025.
Biorevert currently has seven pipelines under development both autonomously and collaboratively with leading biotech companies in south Korea. Four of their pipelines in the process of hit-finding, and other three pipelines are in the hit-to-lead process. They are also autonomously developing one of their pipelines as a small molecule and a gene therapy using adeno-associated virus, which is currently in in vivo Proof of Concept process.
For further information, please visit www.biorevert.com.
Contacts
Biorevert
Sea Choi
Co-founder and Chief Global Strategist
T +82 70-8787-8252
Email: cgs@biorevert.com